<p><strong>Athira Pharma Inc.</strong> (NASDAQ: ATHA) 股票在周四交易上涨，交易量为 5729 万股，而根据 Benzinga Pro 的数据，平均交易量为 30940 股。</p>
<p>Athira Pharma 周四同意收购 lasofoxifene 的开发和商业化权利，该资产正在进行潜在的注册性三期临床试验。</p>
<p>正在进行的三期 ELAINE-3 临床试验的入组率超过 50%，预计将在 2027 年中期公布数据。</p>
<p>Athira 已从 <strong>Sermonix Pharmaceuticals, Inc</strong>. 获得全球独占许可（不包括亚洲和中东某些国家），以开发和商业化 lasofoxifene 用于 转移性乳腺癌。</p>
<p><strong><em>另请阅读: 辉瑞的 Tukysa 联合疗法在转移性乳腺癌中显示出强大的无进展生存期获益</em></strong></p>
<h2>Sermonix 许可协议</h2>
<p>Athira 将向 Sermonix 发行一份预先融资的认股权证，以购买约 550 万股，行使价格为每股 0.001 美元，作为部分对价。</p>
<p>如果 Athira 达到某些商业化或年度净销售里程碑，还需向 Sermonix 支付最高达 1 亿美元的款项。</p>
<h2>融资</h2>
<p>Athira 还宣布进行 9000 万美元的私募融资，包括普通股和认股权证，认股权证的行使可提供最多 146 百万美元的额外资金，以支持新项目的开发，直至关键的临床 和监管里程碑。</p>
<p>公司预计这笔前期融资将支持 lasofoxifene 的开发，直至其顶线数据公布和关键监管里程碑，资金充足可持续到 2028 年。</p>
<p>Athira 打算将净收益用于资助 lasofoxifene 针对耐药性转移性乳腺癌的开发，以及其管道中的其他临床资产，并用于营运资金和一般企业用途。</p>
<p><strong>ATHA 价格动态：</strong> 截至周四发布时，Athira Pharma 的股票上涨了 74.49%，报 7.22 美元。该股票交易价格创下 52 周新高， 根据 Benzinga Pro 数据。</p>
<p><strong>接下来阅读</strong>:</p>
<ul>
<li><strong><em>白宫准备与 AbbVie、诺华、罗氏达成药品价格交易</em></strong></li>
</ul>
<p><em>图片来源于 Shutterstock</em></p>

ATHA

<p>Athira Pharma 的股票在获得拉索福辛的第三阶段权利并 secured 9000 万美元融资后飙升了 74.49%。该公司从 Sermonix Pharmaceuticals 获得了一个独家的全球许可（不包括亚洲和某些中东国家），用于开发和商业化拉索福辛治疗转移性乳腺癌。这笔融资将 Athira 的现金流延续至 2028 年。该股票的交易量达到 5729 万，远高于平均的 3.094 万</p>

<p><strong>Athira Pharma Inc.</strong> (NASDAQ: ATHA) stock is trading higher on Thursday, with a session volume of 57.29 million compared to the average volume of 30.94 thousand as per data from Benzinga Pro.</p>
<div class="lb-trans"><p><strong>Athira Pharma Inc.</strong> (NASDAQ: ATHA) 股票在周四交易上涨，交易量为 5729 万股，而根据 Benzinga Pro 的数据，平均交易量为 30940 股。</p>
</div><p>Athira Pharma on Thursday agreed to acquire the rights for the development and commercialization of lasofoxifene, a clinical asset in a potentially registrational Phase 3 trial.</p>
<div class="lb-trans"><p>Athira Pharma 周四同意收购 lasofoxifene 的开发和商业化权利，该资产正在进行潜在的注册性三期临床试验。</p>
</div><p>The ongoing Phase 3 ELAINE-3 clinical trial is greater than 50% enrolled, with data expected in mid-2027.</p>
<div class="lb-trans"><p>正在进行的三期 ELAINE-3 临床试验的入组率超过 50%，预计将在 2027 年中期公布数据。</p>
</div><p>Athira has acquired an exclusive global license (excluding Asia and certain countries in the Middle East) from <strong>Sermonix Pharmaceuticals, Inc</strong>. for rights to develop and commercialize lasofoxifene for metastatic breast cancer.</p>
<div class="lb-trans"><p>Athira 已从 <strong>Sermonix Pharmaceuticals, Inc</strong>. 获得全球独占许可（不包括亚洲和中东某些国家），以开发和商业化 lasofoxifene 用于 转移性乳腺癌。</p>
</div><p><strong><em>Also Read: Pfizer’s Tukysa Combo Shows Strong PFS Benefit In Metastatic Breast Cancer</em></strong></p>
<div class="lb-trans"><p><strong><em>另请阅读: 辉瑞的 Tukysa 联合疗法在转移性乳腺癌中显示出强大的无进展生存期获益</em></strong></p>
</div><h2>Sermonix License Agreement</h2>
<div class="lb-trans"><h2>Sermonix 许可协议</h2>
</div><p>Athira will issue to Sermonix, as partial consideration, a pre-funded warrant to purchase approximately 5.5 million shares, with an exercise price of $0.001 per share.</p>
<div class="lb-trans"><p>Athira 将向 Sermonix 发行一份预先融资的认股权证，以购买约 550 万股，行使价格为每股 0.001 美元，作为部分对价。</p>
</div><p>Athira will also be obligated to make certain payments to Sermonix of up to $100.0 million if Athira achieves certain commercialization or annual net sales milestones.</p>
<div class="lb-trans"><p>如果 Athira 达到某些商业化或年度净销售里程碑，还需向 Sermonix 支付最高达 1 亿美元的款项。</p>
</div><h2>Financing</h2>
<div class="lb-trans"><h2>融资</h2>
</div><p>Athira also announced an upfront financing of $90 million in private placement financing of common stock and warrants, with the warrants providing, if exercised, up to an additional $146 million to support development of the new program through key clinical and regulatory milestones.</p>
<div class="lb-trans"><p>Athira 还宣布进行 9000 万美元的私募融资，包括普通股和认股权证，认股权证的行使可提供最多 146 百万美元的额外资金，以支持新项目的开发，直至关键的临床 和监管里程碑。</p>
</div><p>The company anticipates the upfront financing will support lasofoxifene development through its topline data readout and key regulatory milestones, with sufficient capital for runway into 2028.</p>
<div class="lb-trans"><p>公司预计这笔前期融资将支持 lasofoxifene 的开发，直至其顶线数据公布和关键监管里程碑，资金充足可持续到 2028 年。</p>
</div><p>Athira intends to use the net proceeds to fund the development of lasofoxifene for treatment-resistant metastatic breast cancer, and other clinical assets in its pipeline, and for working capital and general corporate purposes.</p>
<div class="lb-trans"><p>Athira 打算将净收益用于资助 lasofoxifene 针对耐药性转移性乳腺癌的开发，以及其管道中的其他临床资产，并用于营运资金和一般企业用途。</p>
</div><p><strong>ATHA Price Action:</strong> Athira Pharma shares were up 74.49% at $7.22 at the time of publication on Thursday. The stock is trading at a new 52-week high, according to Benzinga Pro data.</p>
<div class="lb-trans"><p><strong>ATHA 价格动态：</strong> 截至周四发布时，Athira Pharma 的股票上涨了 74.49%，报 7.22 美元。该股票交易价格创下 52 周新高， 根据 Benzinga Pro 数据。</p>
</div><p><strong>Read Next</strong>:</p>
<div class="lb-trans"><p><strong>接下来阅读</strong>:</p>
</div><ul>
<li><strong><em>White House Readies Drug Price Deals With AbbVie, Novartis, Roche</em></strong></li>
</ul>
<div class="lb-trans"><ul>
<li><strong><em>白宫准备与 AbbVie、诺华、罗氏达成药品价格交易</em></strong></li>
</ul>
</div><p><em>Photo via Shutterstock</em></p>
<div class="lb-trans"><p><em>图片来源于 Shutterstock</em></p>
</div>

为什么 Athira Pharma 的股票在收购乳腺癌相关资产后出现飙升？